TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03884517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8003
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT03651115

Intervention type: DIAGNOSTIC_TEST
Intervention: therapeutic drug monitoring
Description: To monitor the blood concentrations of gentamicin and vancomycin

Intervention type: DIAGNOSTIC_TEST
Intervention: therapeutic drug monitoring
Description: To monitor the blood concentrations of gentamicin and vancomycin
Study: NCT01489215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: presence
Description: constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: checking
Description: putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
Study: NCT04412343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group Intervention
Description: Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Exercise Intervention
Description: Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
Study: NCT03774524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol subligual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol subligual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to TA
Description: 110 ml saline iv
Study: NCT02218736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: Oral dosing of 10 mg CERC-501 daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral dosing of 10 mg placebo daily for 8 weeks
Study: NCT04359095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Pill
Description: Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
Study: NCT04538963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Band affixed with Glass Ionomer Cement
Description: Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
Study: NCT04209972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Ultra-High-Resolution CT scanner
Description: Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genesis high-end CT scanner
Description: Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
Study: NCT01461200

Intervention type: OTHER
Intervention: Swab of vestibule and middle meatus of nose
Description: Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season

Intervention type: OTHER
Intervention: Swab of vestibule and middle meatus of nose
Description: Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
Study: NCT03329118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824, Simvastatin
Description: two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
Study: NCT04299997

Intervention type: OTHER
Intervention: Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
Description: 1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone
Study: NCT01047345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V503
Description: V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V503
Description: Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
Study: NCT04485052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: anti-CD47 Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: anti-CD47 Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Demethylation drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Demethylation drugs
Study: NCT03925233

Intervention type: DRUG
Intervention: Vinorelbine tartrate
Description: Vinorelbine tartrate injection

Intervention type: DRUG
Intervention: Vinorelbine tartrate
Description: Vinorelbine tartrate injection

Intervention type: DRUG
Intervention: Vinorelbine tartrate
Description: Vinorelbine tartrate injection

Intervention type: DRUG
Intervention: Carboplatin
Description: Carboplatin injection

Intervention type: DRUG
Intervention: Carboplatin
Description: Carboplatin injection

Intervention type: DRUG
Intervention: Carboplatin
Description: Carboplatin injection

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate injection

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate injection

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate injection

Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Eribulin mesylate injection

Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Eribulin mesylate injection

Intervention type: DRUG
Intervention: Eribulin mesylate
Description: Eribulin mesylate injection

Intervention type: DRUG
Intervention: Toremifene citrate
Description: Toremifene citrate tablets

Intervention type: DRUG
Intervention: Toremifene citrate
Description: Toremifene citrate tablets

Intervention type: DRUG
Intervention: Toremifene citrate
Description: Toremifene citrate tablets

Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole tablets
Study: NCT04069247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT-I
Description: The e-CBT-I will be delivered through a mobile application (eSleep) with a personal password.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-HE
Description: The e-HE will be delivered in control though a mobile application (eSleep) with a personal password.
Study: NCT00762723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinica Anterior Lumbar Plate System
Description: Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
Study: NCT00382408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DR-5001
Description: All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
Study: NCT03925233

Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole tablets

Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole tablets

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole tablets
Study: NCT00382408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
Study: NCT03925233

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole tablets

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole tablets

Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane tablets

Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane tablets

Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane tablets

Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant injection

Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant injection

Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant injection
Study: NCT01996397

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac resynchronization therapy device implantation
Study: NCT01792583

Intervention type: DRUG
Intervention: Modafinil/armodafinil

Intervention type: DRUG
Intervention: Modafinil/armodafinil
Study: NCT03925233

Intervention type: DRUG
Intervention: Olaparib
Description: Olapani pill
Study: NCT01347281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of [18F]HX4
Description: Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position
Study: NCT00616486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: 6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo)
Description: Sham treatment will mimic active treatment mentioned above.
Study: NCT02206464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Shanghai/02/2013 (H7N9) MIV
Description: Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Shanghai/02/2013 (H7N9) MIV
Description: Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Shanghai/02/2013 (H7N9) MIV
Description: Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
Study: NCT03925233

Intervention type: DRUG
Intervention: Olaparib
Description: Olapani pill

Intervention type: DRUG
Intervention: Olaparib
Description: Olapani pill

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab injection

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab injection

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab injection

Intervention type: DRUG
Intervention: Apatinib mesylate
Description: Apatinib mesylate tablets

Intervention type: DRUG
Intervention: Apatinib mesylate
Description: Apatinib mesylate tablets

Intervention type: DRUG
Intervention: Apatinib mesylate
Description: Apatinib mesylate tablets

Intervention type: DRUG
Intervention: Pattozumab
Description: Pattozumab injection

Intervention type: DRUG
Intervention: Pattozumab
Description: Pattozumab injection

Intervention type: DRUG
Intervention: Pattozumab
Description: Pattozumab injection

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine tablets

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine tablets

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine tablets

Intervention type: DRUG
Intervention: Ear particles
Description: Ear particles

Intervention type: DRUG
Intervention: Ear particles
Description: Ear particles

Intervention type: DRUG
Intervention: Ear particles
Description: Ear particles

Intervention type: DRUG
Intervention: Aidi Injection
Description: Aidi Injection

Intervention type: DRUG
Intervention: Aidi Injection
Description: Aidi Injection

Intervention type: DRUG
Intervention: Aidi Injection
Description: Aidi Injection

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection
Study: NCT01187771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Gastric Banding
Description: Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
Study: NCT03999827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycaemic Index Diet
Description: Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Diet
Description: Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
Study: NCT03036865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered IV or SC
Study: NCT03994042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mental imagery neurofeedback training
Description: Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
Study: NCT00744094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein drink
Description: 250 ml protein hydrolysate solution

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: 12 weeks resistance training, 3 days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks resistance training, 3 days per week
Study: NCT03688152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study.